Invitation to Press Conference: Alzheimer's Breakthrough - Live Webcast of Worldwide Press Conference - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Invitation to Press Conference: Alzheimer's Breakthrough - Live Webcast of Worldwide Press Conference


Invitation to Press Conference: Alzheimer's Breakthrough - Live Webcast of Worldwide Press Conference

PR Newswire

VIENNA, Austria, May 27, 2014 /PRNewswire/ --

AFFiRiS AG Presents Clinical Phase II Data 

Wednesday, 4 June 2014  

10.00 am CEST (Central European Summer Time) 

08.00 am UTC (Coordinated Universal Time)  

Live webcast link:   http://webtv.braintrust.at/affiris/2014-06-04/    

(A recording of the webcast will be available right after the press conference at the aforementioned link.)

AFFiRiS AG, Vienna, Austria will present final data of a clinical trial phase II of its proprietary Alzheimer's therapy. More than 300 patients were included in the international multi-centric clinical trial and significant effects have been observed.

Data will be presented by

Dr. Walter Schmidt, CEO & Co-founder AFFiRiS AG

Dr. Frank Mattner, CSO & Co-founder AFFiRiS AG

The conference will take place at the Vienna Marriott Hotel, Parkring 12a, 1010 Vienna, Room Sachsen Coburg at 10.00 am CEST. If you are unable to attend please visit the aforementioned web link for a live webcast of the press conference. An embedded message board will allow you to participate in the Q&A round. A recording of the conference will be made available at the following link immediately after the press conference: http://webtv.braintrust.at/affiris/2014-06-04/.

Should you wish for a (telephone) interview after the press conference please contact AFFiRiS' press agency PR&D (see below). Interview slots will be allocated strictly on a first come, first served policy.

Photos of the press conference will be available at 2 pm CEST (12 UTC) here: http://www.apa-fotoservice.at/galerie/5480

About AFFiRiS AG

Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines (and more) for Alzheimer's disease, Atherosclerosis, Parkinson's disease, diabetes and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. AFFiRiS currently employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria (http://www.affiris.com).

PR&D - Public Relations for Research & Education
Nina Honzik or Judith Sandberger
T +43-1-505-70-44
F +43-1-505-50-83
E honzik@prd.at or sandberger@prd.at
Mariannengasse 8
1090 Vienna, Austria
http://www.prd.at


SOURCE AFFiRiS AG

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here